Misinformation is a public health crisis - here's how to fix it
Episode
50 min
Read time
2 min
Topics
Health & Wellness, Relationships, Investing
AI-Generated Summary
Key Takeaways
- ✓Misinformation mechanism: Health misinformation spreads because it exploits bounded rationality — humans default to authority-seeming figures rather than scrutinizing credentials. The fix is not canceling bad actors but replicating their short-form, engaging delivery format with credible, data-backed content from institutions like MD Anderson, which carry automatic credibility advantages.
- ✓Nutraceutical Wild West: Supplements and nutraceuticals operate under a single regulatory principle — if not acutely toxic, any claim is permissible on packaging. Research by André Meyer found nearly no supplement manufacturers met the purity levels stated on their labels, yet the category remains a multi-billion-dollar revenue engine with minimal accountability.
- ✓Longevity investing discipline: Longevicy reviewed 2,800 companies for Fund One and invested in 20 — under 1% conversion. The filter: disease-specific therapeutics targeting age-related conditions with measurable health span outcomes, not lifespan claims. Avoiding catch-all aging language and requiring FDA-viable disease indications separates investable companies from capital-wasting hype plays.
- ✓AI drug discovery momentum: Portfolio company advances in macrocycle design have generated deals worth $1.5B with Organon and $1.7B with Novartis, including $100M upfront. AI for drug discovery is most valuable for previously undruggable targets and rare diseases, functioning as a complement to big pharma's distribution and manufacturing infrastructure rather than a replacement.
- ✓Personal misinformation defense: Cross-reference any health advice encountered online with a treating physician or GP before acting, particularly for chronic conditions. Start with committing to regular checkups at certified medical institutions to generate personal baseline data. This two-step habit — verified data plus professional cross-referencing — reduces vulnerability to harmful unproven interventions.
What It Covers
Sergei Jakimov, founding partner of Longevicy VC, argues that health misinformation on social media constitutes a public health crisis, driven by bounded rationality and credibility gaps. He outlines how scientific institutions can reclaim audience trust by adopting the same accessible communication formats used by wellness influencers.
Key Questions Answered
- •Misinformation mechanism: Health misinformation spreads because it exploits bounded rationality — humans default to authority-seeming figures rather than scrutinizing credentials. The fix is not canceling bad actors but replicating their short-form, engaging delivery format with credible, data-backed content from institutions like MD Anderson, which carry automatic credibility advantages.
- •Nutraceutical Wild West: Supplements and nutraceuticals operate under a single regulatory principle — if not acutely toxic, any claim is permissible on packaging. Research by André Meyer found nearly no supplement manufacturers met the purity levels stated on their labels, yet the category remains a multi-billion-dollar revenue engine with minimal accountability.
- •Longevity investing discipline: Longevicy reviewed 2,800 companies for Fund One and invested in 20 — under 1% conversion. The filter: disease-specific therapeutics targeting age-related conditions with measurable health span outcomes, not lifespan claims. Avoiding catch-all aging language and requiring FDA-viable disease indications separates investable companies from capital-wasting hype plays.
- •AI drug discovery momentum: Portfolio company advances in macrocycle design have generated deals worth $1.5B with Organon and $1.7B with Novartis, including $100M upfront. AI for drug discovery is most valuable for previously undruggable targets and rare diseases, functioning as a complement to big pharma's distribution and manufacturing infrastructure rather than a replacement.
- •Personal misinformation defense: Cross-reference any health advice encountered online with a treating physician or GP before acting, particularly for chronic conditions. Start with committing to regular checkups at certified medical institutions to generate personal baseline data. This two-step habit — verified data plus professional cross-referencing — reduces vulnerability to harmful unproven interventions.
Notable Moment
Jakimov reframes the misinformation problem through Kantian ethics: spreading false health advice is not merely morally wrong but actively removes an individual's freedom to make informed choices — a philosophical framing that shifts responsibility squarely onto those profiting from unverified health claims.
You just read a 3-minute summary of a 47-minute episode.
Get Beyond Biotech summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from Beyond Biotech
This nonprofit is building the ecosystem to cure epidermolysis bullosa
Jul 24 · 40 min
In Good Company with Nicolai Tangen
Mala Gaonkar: Building SurgoCap, Identifying Great Businesses and Learning from Mistakes
Jan 21
More from Beyond Biotech
How BIO-Europe is expanding beyond dealmaking in 2026
Jul 17 · 25 min
The Diary of a CEO
Vitamin D Expert: The Supplement World Is Giving The WRONG Advice!
Jul 27
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links.
company
“The fix is not canceling bad actors but replicating their short-form, engaging delivery format with credible, data-backed content from institutions like MD Anderson, which carry automatic credibility advantages.”
“Portfolio company advances in macrocycle design have generated deals worth $1.5B with Organon and $1.7B with Novartis, including $100M upfront.”
“Portfolio company advances in macrocycle design have generated deals worth $1.5B with Organon and $1.7B with Novartis”
- Longevicy VCBy guest
“Sergei Jakimov, founding partner of Longevicy VC, argues that health misinformation on social media constitutes a public health crisis”
More from Beyond Biotech
We summarize every new episode. Want them in your inbox?
This nonprofit is building the ecosystem to cure epidermolysis bullosa
How BIO-Europe is expanding beyond dealmaking in 2026
Turning cancer cell dependencies into targeted therapies
The first PROTAC is here. What comes next in protein degradation?
De-risking neurology drug development with better mouse models
Similar Episodes
Related episodes from other podcasts
In Good Company with Nicolai Tangen
Jan 21
Mala Gaonkar: Building SurgoCap, Identifying Great Businesses and Learning from Mistakes
The Diary of a CEO
Jul 27
Vitamin D Expert: The Supplement World Is Giving The WRONG Advice!
The Mel Robbins Podcast
Jul 23
#1 Hormone Doctor: The Ultimate Guide to Perimenopause, Fertility, Birth Control, PCOS, & Menopause
The Mel Robbins Podcast
Jul 16
How to Increase Your Emotional Intelligence & Never Get Angry or Bothered by Anyone
20VC (20 Minute VC)
Jul 6
20VC: Why Now is the Time for the Application Layer | Why OpenAI & Anthropic Won't Win the App Layer | Why Startups Should be TokenMaxxing | Why VCs Should Reduce Weighting on Price & Ownership in an Age of AI with Mike Mignano, USV
Explore Related Topics
This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into Beyond Biotech.
Every Monday, we deliver AI summaries of the latest episodes from Beyond Biotech and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime